PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME
Clinical trials for PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Horse antibody cocktail aims to revive blood cell production
Disease control Recruiting nowThis phase 2 trial tests a combination of horse anti-thymocyte globulin, cyclosporine, steroids, and a growth factor in 140 adults with aplastic anemia or low-risk myelodysplastic syndrome. The goal is to see if this immune-suppressing and blood-cell-boosting approach can improve…
Matched conditions: PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 16:48 UTC
-
Personalized immune cells aim to stop blood cancer relapse after transplant
Disease control Recruiting nowThis phase II trial tests whether giving patients personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help prevent their blood cancer from returning. The study includes 100 people with various blood cancers like leukemia, lymphoma, and myelom…
Matched conditions: PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New chemo cocktail targets tough leukemias
Disease control Recruiting nowThis phase 2 trial is testing a combination of four chemotherapy drugs—cladribine, idarubicin, cytarabine, and venetoclax—in people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blast-phase chronic myeloid leukemia. The goal is to see if this mix can kill ca…
Matched conditions: PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
Engineered virus targets Hard-to-Treat blood cancers in new trial
Disease control Recruiting nowThis early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…
Matched conditions: PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC